The Valley Desk

NCT02296242 · Interventional trial

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Overall registry status Completed

Phase 1 · Phase 2

Conditions Acute Myelogenous Leukemia, Myelodysplastic Syndrome

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov